This activity is funded by an independent medical education grant from ViiV Healthcare.

This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download slides
    Download slides
    Download slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Anne-Mieke Vandamme

    Katholieke Universiteit Leuven,
    Leuven, Belgium

    Anne-Mieke Vandamme is a full professor in the medical faculty at the Katholieke Universiteit (KU) Leuven, in Belgium, where she also teaches evolutionary genetics and bioinformatics. She is the head of the Institute of the Future, a transdisciplinary research incubator at KU. read more

    Prof. Vandamme and her team research the molecular epidemiology of HIV, HTLV, HCV and arboviruses; HIV and HCV drug resistance testing in clinical context; and bioinformatic tools. She has extensive and widely recognized expertise in molecular epidemiology and drug resistance. She has been participating in several European projects (currently ZIKAlliance and STEAM+), and supported the development of widely used bioinformatic tools: the Rega HIV drug resistance algorithm, the Rega HIV typing and subtyping tool and RegaDB. At the Institute of the Future, she coaches teams that incubate transdisciplinary research projects geared towards the United Nations Sustainable Development Goals.

    She has authored more than 400 publications in international journals such as Lancet, Nature Medicine, Lancet Infectious Diseases, PNAS, Journal of Virology and Trends in Microbiology.

    Prof. Anne-Mieke Vandamme has no interests/relationships or affiliations to disclose in relation to this activity.
    Prof. José Arribas

    La Paz Hospital,
    Madrid, Spain

    José Arribas is the head of the Internal Medicine Department at La Paz University Hospital and a professor of medicine at Autonoma University Medical School in Madrid, Spain. read more

    Prof. Arribas is research director of HIV and infectious diseases at La Paz Hospital where his research interests include antiretroviral therapy, development of new antiretrovirals and emerging infectious diseases. Prof. Arribas is the former president of GeSIDA (Spanish group for AIDS research) and the former chair of the antiretroviral panel of the European AIDS Clinical Society. 

    He is the author of more than 400 scientific papers, many of them clinical trial reports on antiretroviral therapy.

    Prof. José Arribas discloses:  Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from AbbVie, Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from ViiV Healthcare.
    Prof. Antonella Castagna

    Vita-Salute San Raffaele University, Milan, Italy

    Antonella Castagna is the head of the Infectious Diseases Clinic at Vita-Salute University, San Raffaele Scientific Institute in Milan, Italy. read more

    Prof. Castagna’s research is focused on HIV therapeutic approaches, with particular attention to heavily pre-treated patients with multidrug resistant HIV infection. She is co-author of more than 500 scientific publications.

    Prof. Antonella Castagna discloses: Advisory board or panel fees from Gilead Sciences, Janssen-Cilag and MSD. Grants/research support from ViiV Healthcare.
    Back to Faculty
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    SEE ALL VIDEOS
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    How confident are you in testing for and managing ART resistance?

    Submit your answer to see the results

    Not confident
       
    A little confident
       
    Moderately confident
       
    Very confident
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    In the absence of specific contraindications, which initial ART regimen do you normally recommend?

    Submit your answer to see the results

    Three-drug: Two NRTIs + one INSTI
       
    Two-drug: One NRTI + one INSTI
       
    Three-drug: Two NRTIs + one NNRTI
       
    Three-drug: Two NRTIs + one boosted PI
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    How confident are you in describing the virology and life cycle of HIV?

    Submit your answer to see the results

    Not confident
       
    A little confident
       
    Moderately confident
       
    Very confident
       
     
    Expert Interviews

    touchEXPERT OPINIONS
    Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

    Demystifying virology: The link between the HIV life cycle and ART

    Take CE/CME Test

    Anne-Mieke Vandamme is a full professor in the medical faculty at the Katholieke Universiteit (KU) Leuven, in Belgium, where she also teaches evolutionary genetics and bioinformatics. She is the head of the Institute of the Future, a transdisciplinary research incubator at KU. read more

    Prof. Vandamme and her team research the molecular epidemiology of HIV, HTLV, HCV and arboviruses; HIV and HCV drug resistance testing in clinical context; and bioinformatic tools. She has extensive and widely recognized expertise in molecular epidemiology and drug resistance. She has been participating in several European projects (currently ZIKAlliance and STEAM+), and supported the development of widely used bioinformatic tools: the Rega HIV drug resistance algorithm, the Rega HIV typing and subtyping tool and RegaDB. At the Institute of the Future, she coaches teams that incubate transdisciplinary research projects geared towards the United Nations Sustainable Development Goals.

    She has authored more than 400 publications in international journals such as Lancet, Nature Medicine, Lancet Infectious Diseases, PNAS, Journal of Virology and Trends in Microbiology.

    Prof. Anne-Mieke Vandamme has no interests/relationships or affiliations to disclose in relation to this activity.

    Take CE/CME Test

    José Arribas is the head of the Internal Medicine Department at La Paz University Hospital and a professor of medicine at Autonoma University Medical School in Madrid, Spain. read more

     

    Prof. Arribas is research director of HIV and infectious diseases at La Paz Hospital where his research interests include antiretroviral therapy, development of new antiretrovirals and emerging infectious diseases. Prof. Arribas is the former president of GeSIDA (Spanish group for AIDS research) and the former chair of the antiretroviral panel of the European AIDS Clinical Society. 

    He is the author of more than 400 scientific papers, many of them clinical trial reports on antiretroviral therapy.

    Prof. José Arribas Discloses:  Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from AbbVie, Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from ViiV Healthcare.

    Take CE/CME Test

    Antonella Castagna is the head of the Infectious Diseases Clinic at Vita-Salute University, San Raffaele Scientific Institute in Milan, Italy. read more

    Prof. Castagna’s research is focused on HIV therapeutic approaches, with particular attention to heavily pre-treated patients with multidrug resistant HIV infection. She is co-author of more than 500 scientific publications.

    Prof. Antonella Castagna Discloses: Advisory board or panel fees from Gilead Sciences, Janssen-Cilag and MSD. Grants/research support from ViiV Healthcare.

    Take CE/CME Test
    Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives
    • Outline the virology of the HIV life cycle and how it is targeted by different antiretroviral therapies
    • Summarize the mechanism of action of current available antiretroviral therapies and the rationale for combining them
    • Discuss the risk of resistance to currently available antiretrovirals and strategies to monitor and manage resistance
    Overview

    In this activity, three HIV experts share their insights on the virology of HIV, the rationale for multidrug antiretroviral therapy (ART) regimens, the mechanisms by which ART resistance develops and how to manage it in people living with HIV.

    This activity is provided by touchIME.

    Target Audience

    This activity has been designed to meet the educational needs of primary care physicians, HIV specialists, infectious disease specialists, genitourinary medicine specialists, specialist nurse practitioners and virologists involved in the management of HIV.

    Faculty

    Prof. Anne-Mieke Vandamme has no interests/relationships or affiliations to disclose in relation to this activity.

    Prof. José Arribas discloses:  Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from AbbVie, Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from ViiV Healthcare.

    Prof. Antonella Castagna discloses: Advisory board or panel fees from Gilead Sciences, Janssen-Cilag and MSD. Grants/research support from ViiV Healthcare.

    Touch Medical Contributors

    Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

    Date of original release: 31 July 2024. 

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Evolving HIV diagnostic technologies: A new era of precision

    GO TO HUB

    JOURNALS

    Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV

    GO TO ARTICLE

    touchIN CONVERSATION

    Practical considerations for COVID-19 vaccination in the Middle East

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Reducing transmission of COVID-19: Spotlight on vaccines

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Cabotegravir and Rilpivirine Long-acting Injectable Therapy for Human Immunodeficiency Virus

    GO TO ARTICLE

    CONFERENCE HUB

    Craig Hoesley, HIVR4P 2021: Intrarectal Microbicides for HIV Prevention (Part 1)

    GO TO HUB

    Topics covered in this activity

    HIV / Sexually Transmitted Infections / Viral Infections
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 31 July 2024.

    Claim Credit
    touchEXPERT OPINIONS
    Demystifying virology: The link between the HIV life cycle and ART

    You may also be interested in...

    JOURNALS

    Bictegravir / Emtricitabine / Tenofovir Alafenomide for the Treatment of HIV / Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients

    GO TO ARTICLE

    touchTALKS

    COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in Africa and the Middle East?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    HIV Prevention Utilizing Long-acting Injectables

    GO TO ARTICLE

    touchEXPERT OPINIONS

    Cytomegalovirus in solid organ transplant recipients: Management strategies and emerging therapeutic options

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    Ole Schmeltz Søgaard

    CONFERENCE HUB

    Ole Schmeltz Søgaard, CROI 2022: Current Status and Future Potential of Broadly Neutralising anti-HIV-1 Antibodies

    GO TO HUB

    CONFERENCE HUB

    Tomas Jelinek: Unmet Needs, Prevention and Treatment of Chikungunya Virus

    GO TO HUB
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 31 July 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72